Oragenics Agrees to Obtain up to $9 Million in Equity Financing

Oragenics announced that it has entered into an agreement to obtain up to $9 million in equity financing from Fusion Capital Fund II, LLC, a Chicago-based institutional investor. Under the agreement, Fusion Capital has agreed to purchase up to $9 million of newly issued Oragenics stock over a period of up to 30 months. Oragenics has the right to control the timing and the amount of stock sold, if any, to Fusion Capital.

()a href="http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050524005367&ndmHsc=v2*A1116327600000*B1116969866000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view" target="_blank">BioSpace